HuGE Literature Finder
Records
1
-
2
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget 2018 Jan 9 (8): 7859-7866. Cremolini Chiara, Del Re Marzia, Antoniotti Carlotta, Lonardi Sara, Bergamo Francesca, Loupakis Fotios, Borelli Beatrice, Marmorino Federica, Citi Valentina, Cortesi Enrico, Moretto Roberto, Ronzoni Monica, Tomasello Gianluca, Zaniboni Alberto, Racca Patrizia, Buonadonna Angela, Allegrini Giacomo, Ricci Vincenzo, Di Donato Samantha, Zagonel Vittorina, Boni Luca, Falcone Alfredo, Danesi Roma |
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study. Anticancer research 2014 Jan 34 (1): 195-201. Hirata Keiji, Nagata Naoki, Kato Takeshi, Okuyama Yusuke, Andoh Hideaki, Takahashi Kenichi, Oba Koji, Sakamoto Junichi, Hazama Shoichi, Mishima Hideyu |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 22, 2022
- Content source: